-

Aizon Launches Predictive Maintenance Solution for Pharmaceutical Manufacturing

Aizon Asset Health helps pharmaceutical manufacturers and biotech companies optimize the performance of their equipment and other assets through intelligent, real-time monitoring and alerting

SAN FRANCISCO--(BUSINESS WIRE)--Aizon announced today the launch of its new asset monitoring application for pharmaceutical manufacturers and biotech companies. Built on Aizon’s GxP compliant AI SaaS Platform, Aizon Asset Health provides intelligent historical maintenance analysis, proactively monitors the condition of critical assets in real time, identifies potential problems and provides actionable maintenance recommendations that keep equipment up and running optimally. This data-driven maintenance approach reduces maintenance costs, eliminates unplanned downtime and optimizes product yield—unlocking the full potential of Smart Pharma Manufacturing.

Keeping manufacturing assets in effective working order can be costly and wasteful. A schedule-based approach to maintenance often results in the unnecessary repair or replacement of equipment in acceptable working conditions or conversely results in catastrophic failure of equipment due to undiagnosed issues. This can cause production disruptions, lead to product rejection, impact time to market and compromise First Time Right, that is ensuring that any procedure is performed in the right manner the first time and every time. Using advanced analytics and multivariate analysis, together with artificial intelligence, the Aizon Asset Health application further optimizes the reduction in unplanned downtime through condition-based maintenance beyond today’s industry standard - ultimately reducing maintenance expenses while improving asset reliability and performance.

“Pharmaceutical manufacturers and biotech companies are under tremendous pressure to maximize the return on investment and to reduce unplanned downtime; however, traditional schedule-based maintenance approach tends to fall short in terms of gaining control of downtime and the high costs associated with replacing equipment in an effort to achieve better performance,” said John Vitalie, CEO, Aizon. “Our Asset Health application enables our customers to harness the power of their equipment and environmental data to slash maintenance costs, optimize equipment performance, enhance product output and improve product quality.”

Intelligent, Real-Time Asset Monitoring Across Equipment and Facilities

The Aizon Asset Health application allows pharmaceutical manufacturers and biotech companies to leverage predictive power to monitor the health of assets, and—based on the prescriptive and conditional data-driven insights that the solution provides—receive advanced warnings on their conditions. These actionable insights empower operators and maintenance teams to react and intervene in real time and keep production lines up and running. A cloud native application, Asset Health can be scaled across multiple facilities and locations and provide a historical record and status of all equipment.

This allows pharmaceutical manufacturers and biotech companies to ensure complete asset integrity, maintain optimal facility conditions (such as temperature, humidity and vibrations), predict the expected lifespan of equipment and track the energy an asset has consumed and its CO2 emissions. These critical insights are consolidated on a single dashboard specifically customized to manage any organization’s unique asset maintenance needs.

“Demands on pharmaceutical manufacturing have never been higher, the Aizon Asset Health application helps manufacturers prevent unplanned downtime and maximize product quality and yield,” said Andy Alasso, SVP Product, Aizon. “Aizon Asset Health taps into real-time sensor data, consolidates it, and leverages AI to generate alarms and/or actionable insights to optimize asset performance. It’s a game changer for the industry.”

Aizon Asset Health is generally available now globally.

About Aizon

Aizon is an AI software provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within highly regulated industries. The Aizon AI platform seamlessly integrates unlimited sources of structured and unstructured data to deliver actionable insights across all manufacturing sites. Aizon offers an intuitive way to gain meaningful operational intelligence by enabling real-time visibility and predictive insights in a GxP compliant manner with end-to-end data integrity.

Contacts

Noel Ortiz
noel.ortiz@aizon.ai
(+34) 623 04 10 94

Aizon

Details
Headquarters: San Francisco, CA
CEO: Pep Gubau
Employees: 0-1000
Organization: PRI

Release Versions

Contacts

Noel Ortiz
noel.ortiz@aizon.ai
(+34) 623 04 10 94

Social Media Profiles
More News From Aizon

Aizon and Sequence Announce Strategic Partnership to Transform Biopharmaceutical Manufacturing with AI-Powered Solutions

BARCELONA, Spain & RALEIGH, N.C.--(BUSINESS WIRE)--Aizon and Sequence are pleased to announce a new strategic partnership aimed at delivering comprehensive, AI-powered solutions for the pharmaceutical industry. This collaboration will combine Aizon's cutting-edge AI and data analytics platform with Sequence's engineering and compliance expertise to deliver intelligent, compliant, and manufacturing-centric solutions that accelerate digital transformation in regulated environments. Sequence, esta...

Aizon Launches New AI-powered eBR Light Solution to Enhance Manufacturing Productivity in Collaboration with Euroapi

SAN FRANCISCO--(BUSINESS WIRE)--Aizon, an Artificial Intelligence (AI) SaaS provider dedicated to transforming pharmaceutical manufacturing operations, is launching a new product called Aizon Execute, an innovative eBR (Electronic Batch Record) software product, developed in collaboration with Euroapi, a leading global API manufacturer. This collaboration was born out of the need to digitize operations towards more data-driven manufacturing - focusing on the essential user needs while avoiding...

Aizon Announces New Leadership

SAN FRANCISCO--(BUSINESS WIRE)--Aizon (Bigfinite Inc.),  the leader in compliant AI for Biopharma Manufacturing, announced today that John Vitalie will step down as CEO of the company effective as of July 22nd. He will be succeeded by Pep Gubau, founder and CTO, and Executive Chairman of the company. John has led Aizon through a significant growth phase, driven by the development of Aizon’s new commercial strategy and the hiring of a strong team of executives to the organization. “John led a si...
Back to Newsroom